Miss Lucy Hedley

Mortimer Market Centre, London

Switching to rilpivirine in clinical practice: experience of two London HIV units

NJ Marshall[1], L Hedley[2], L Swaden[1], C Smith[2], N Brima[2,3], R Tsintas[1], P Benn[2], M Tyrer[1], L Waters[2], S Edwards[2], MA Johnson[1]

1. Ian Charleson Centre for HIV medicine, Royal Free London NHS Foundation Trust
2. Mortimer Market Unit, Central & North West London NHS Foundation Trust, London, UK
3. Research Department of Infection and Population Health, UCL, London, UK

Baseline characteristics

	All	PI	NNRTI	Other	P*
Number patients, n	169	64	92	13	
Demographics					
Male (n [%])	137 (81)	46 (72)	80 (87)	11 (85)	0.02
Age (median)	43 (38,48)	43 (37,47)	43 (38,49)	47 (41,50)	0.44
White ethnicity(n [%])	105 (62)	35 (55)	58 (63)	12 (92)	0.30
MSM(n [%])	92 (54)	36 (56)	67 (72)	8 (62)	0.08
Treatment history					
Time on cART (mths)	60(25,124)	48(22,99)	61(24,126)	135(78,147)	0.29
Time VL<50c/ml (mths)	32(13,65)	24 (8,52)	36 (17,67)	42 (17,79)	0.06
Number prior cART regimens**	2 (1,3)	2 (1,3)	2 (2,3)	3 (2,4)	0.10
Prior history VF (n [%])	73 (43)	30 (46)	35 (38)	8 (61)	0.27
VL <50c/ml prior to/at switch (n [%])	162 (96)	61 (95)	88 (96)	8 (61)	1.00
Median CD4 prior to/at switch	636 (485,840)	626 473, 791)	660 (500, 840)	833 (537, 960)	0.71

*comparison between PI/r and NNRTI arms **excluding formulation changes All values reported as median (IQR) or percentage unless otherwise stated

Baseline characteristics

	All	PI	NNRTI	Other	P*
Number patients, n	169	64	92	13	
Demographics					
Male (n [%])	137 (81)	46 (72)	80 (87)	11 (85)	0.02
Age (median)	43 (38,48)	43 (37,47)	43 (38,49)	47 (41,50)	0.44
White ethnicity(n [%])	105 (62)	35 (55)	58 (63)	12 (92)	0.30
MSM(n [%])	92 (54)	36 (56)	67 (72)	8 (62)	0.08
Treatment history					
Time on cART (mths)	60(25,124)	48(22,99)	61(24,126)	135(78,147)	0.29
Time VL<50c/ml (mths)	32(13,65)	24 (8,52)	36 (17,67)	42 (17,79)	0.06
Number prior cART regimens**	2 (1,3)	2 (1,3)	2 (2,3)	3 (2,4)	0.10
Prior history VF (n [%])	73 (43)	30 (46)	35 (38)	8 (61)	0.27
VL <50c/ml prior to/at switch (n [%])	162 (96)	61 (95)	88 (96)	8 (61)	1.00
Median CD4 prior to/at switch	636 (485,840)	626 473, 791)	660 (500, 840)	833 (537, 960)	0.71

*comparison between PI/r and NNRTI arms **excluding formulation changes All values reported as median (IQR) or percentage unless otherwise stated

Baseline characteristics

	All	PI	NNRTI	Other	P*
Number patients, n	169	64	92	13	
Demographics					
Male (n [%])	137 (81)	46 (72)	80 (87)	11 (85)	0.02
Age (median)	43 (38,48)	43 (37,47)	43 (38,49)	47 (41,50)	0.44
White ethnicity(n [%])	105 (62)	35 (55)	58 (63)	12 (92)	0.30
MSM(n [%])	92 (54)	36 (56)	67 (72)	8 (62)	0.08
Treatment history					
Time on cART (mths)	60(25,124)	48(22,99)	61(24,126)	135(78,147)	0.29
Time VL<50c/ml (mths)	32(13,65)	24 (8,52)	36 (17,67)	42 (17,79)	0.06
Number prior cART regimens**	2 (1,3)	2 (1,3)	2 (2,3)	3 (2,4)	0.10
Prior history VF (n [%])	73 (43)	30 (46)	35 (38)	8 (61)	0.27
VL <50c/ml prior to/at switch (n [%])	162 (96)	61 (95)	88 (96)	8 (61)	1.00
Median CD4 prior to/at switch	636 (485,840)	626 473, 791)	660 (500, 840)	833 (537, 960)	0.71

*comparison between PI/r and NNRTI arms **excluding formulation changes All values reported as median (IQR) or percentage unless otherwise stated

Baseline characteristics

	All	PI	NNRTI	Other	P*
Number patients, n	169	64	92	13	
Demographics					
Male (n [%])	137 (81)	46 (72)	80 (87)	11 (85)	0.02
Age (median)	43 (38,48)	43 (37,47)	43 (38,49)	47 (41,50)	0.44
White ethnicity(n [%])	105 (62)	35 (55)	58 (63)	12 (92)	0.30
MSM(n [%])	92 (54)	36 (56)	67 (72)	8 (62)	0.08
Treatment history					
Time on cART (mths)	60(25,124)	48(22,99)	61(24,126)	135(78,147)	0.29
Time VL<50c/ml (mths)	32(13,65)	24 (8,52)	36 (17,67)	42 (17,79)	0.06
Number prior cART regimens**	2 (1,3)	2 (1,3)	2 (2,3)	3 (2,4)	0.10
Prior history VF (n [%])	73 (43)	30 (46)	35 (38)	8 (61)	0.27
VL <50c/ml prior to/at switch (n [%])	162 (96)	61 (95)	88 (96)	8 (61)	1.00
Median CD4 prior to/at switch	636 (485,840)	626 473, 791)	660 (500, 840)	833 (537, 960)	0.71

*comparison between PI/r and NNRTI arms **excluding formulation changes All values reported as median (IQR) or percentage unless otherwise stated

Indications for switching

	All	PI	NNRTI	other
CNS side effects	73 (43)	2 (3)	71 (77)	-
Gastrointestinal PI/r	15 (9)	15 (23)	-	-
Hyperlipidaemia	8 (5)	7 (11)	1 (1)	-
Hyperbilirubinaemia (ATV/r)	10 (6)	10 (16)	-	-
Other drug intolerance	17 (10)	6 (10)	8 (9)	3 (23)
From PI monotherapy due to				
Viral failure	1 (0.6)	1 (0.6)	-	-
Patient choice	1 (0.6)	1 (0.6)		
Other (symptomatic)	1 (0.6)	1 (0.6)		
Patient choice				
Requests STR	2 (1)	2 (3)	-	-
Other	4 (2)	4 (6)		
Simplification				
Due to adherence	6 (4)	2 (3)	3 (3)	1 (8)
Without adherence concerns	23 (14)	11 (17)	5 (5)	7 (54)
Other indication	3 (2)	-	1 (1)	2 (15)
Not documented	5 (3)	2 (3)	3 (3)	-

Indications for switching

	All	PI	NNRTI	other
CNS side effects	73 (43)	2 (3)	71 (77)	-
Gastrointestinal PI/r	15 (9)	15 (23)	-	-
Hyperlipidaemia	8 (5)	7 (11)	1 (1)	-
Hyperbilirubinaemia (ATV/r)	10 (6)	10 (16)	-	-
Other drug intolerance	17 (10)	6 (10)	8 (9)	3 (23)
From PI monotherapy due to				
Viral failure	1 (0.6)	1 (0.6)	-	-
Patient choice	1 (0.6)	1 (0.6)		
Other (symptomatic)	1 (0.6)	1 (0.6)		
Patient choice				
Requests STR	2 (1)	2 (3)	-	-
Other	4 (2)	4 (6)		
Simplification				
Due to adherence	6 (4)	2 (3)	3 (3)	1 (8)
Without adherence concerns	23 (14)	11 (17)	5 (5)	7 (54)
Other indication	3 (2)	-	1 (1)	2 (15)
Not documented	5 (3)	2 (3)	3 (3)	-

Indications for switching

	All	PI	NNRTI	other
CNS side effects	73 (43)	2 (3)	71 (77)	-
Gastrointestinal PI/r	15 (9)	15 (23)	-	-
Hyperlipidaemia	8 (5)	7 (11)	1 (1)	-
Hyperbilirubinaemia (ATV/r)	10 (6)	10 (16)	-	-
Other drug intolerance	17 (10)	6 (10)	8 (9)	3 (23)
From PI monotherapy due to				
Viral failure	1 (0.6)	1 (0.6)	-	-
Patient choice	1 (0.6)	1 (0.6)		
Other (symptomatic)	1 (0.6)	1 (0.6)		
Patient choice				
Requests STR	2 (1)	2 (3)	-	-
Other	4 (2)	4 (6)		
Simplification				
Due to adherence	6 (4)	2 (3)	3 (3)	1 (8)
Without adherence concerns	23 (14)	11 (17)	5 (5)	7 (54)
Other indication	3 (2)	-	1 (1)	2 (15)
Not documented	5 (3)	2 (3)	3 (3)	-

Figure 1: Viral load after switch to 2 NRTI + RPV according to prior treatment regimen (discontinuations ignored)



Outcomes

- 30/169 (18%) discontinued RPV after median 6 weeks (IQR 4-13 weeks)
- 3/30 (10%) VL > 50 copies/ml (2 class resistance n=1)
- 16/30 (53%) due to toxicity/intolerance
- 6/30 (20%) due to drug-drug interactions
- 20/30 (67%) switched back to baseline regimen

Conclusions

- Majority of patients switching to rilpivirine maintain virological suppression
- Rates of discontinuation of rilipivirine are higher than anticipated
- Important to discussion other medications and drug-drug interactions prior to switching
- Further data are required